ADVFN - Advanced Financial Network.
HOME» NYSE » G » GSK Stock Price » GSK Stock News

Glaxosmithkline Share News

 Glaxosmithkline Stock Price
GSK Stock Price
 Glaxosmithkline Stock Chart
GSK Stock Chart
 Glaxosmithkline Stock News
GSK Stock News
 Glaxosmithkline Company Information
GSK Company Information
 Glaxosmithkline Stock Trades
GSK Stock Trades

AstraZeneca Needs To Replenish Drug Pipeline - Chairman

By Marta Falconi ZURICH--AstraZeneca PLC (AZN) aims to replenish its thin pipeline of new drugs through external collaborations and by buying drugs in late stages of development from other drugmakers, Chairman Leif Johansson said in an interview Tuesday. His comments come after the company announced it appointed former Roche head of pharma, Pascal Soriot, as chief executive, to succeed David Brennan, who earlier this year retired abruptly amid shareholder dissatisfaction with the company's performance. "There's a number of medicines going off patent," Mr. Johansson said. "We need to replenish them." The U.K.'s No. 2 drug maker by sales, after GlaxoSmithKline PLC (GSK), has suffered a number of expensive drug-development failures, and shown a poor track record in bringing new medicines to market, analysts say. Some of AstraZeneca's biggest drugs are facing, or will soon face, competition from low-cost generics. Mr. Johansson also said that while the pharmaceutical sector is facing challenges, there are also opportunities, such as the possibility of buying buy late-stage drugs, emerging markets and advances in science, including genome technology, which he touted as a way to learn how the human body works and possibly help find new drugs. Write to Marta Falconi at marta.falconi@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Glaxosmithkline (GSK)
DateTimeHeadline
03/31/201509:01:58Why It's Not Too Late to Buy Agenus, Inc. Stock
03/31/201509:01:58Why It's Not Too Late to Buy Agenus, Inc. Stock
03/31/201506:08:023 Cheap Dividend Stocks You Can Buy Right Now
03/30/201513:08:05Report of Foreign Issuer (6-k)
03/30/201512:27:53Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)
03/28/201514:02:03Out of 12 Big Pharma Stocks, This is the 1 You Can Confidently...
03/27/201509:19:49Ebola vaccine candidates pass safety test in in Liberia trials
03/25/201510:43:36Report of Foreign Issuer (6-k)
03/25/201509:03:02Is It Time for GlaxoSmithKline plc to Change Management?
03/25/201503:43:45Sector Leaders Hone 53.52% Edge As Highest Yield, Lowest Price...
03/25/201503:36:149 Top Sector Dividend Dogs Dish Out 22% To 47% March Upsides
03/23/201513:52:00When school is out, science is in! GSK Science in the Summer⢠g...
03/21/201514:58:02Why Itâs Not Too Late to Buy Isis Pharmaceuticals Stock
03/21/201509:40:13GSK And Theravance: Implications Of The Advisory Panel Decision
03/21/201508:11:01Why Pfizer Inc. Isn't Built to Last
03/20/201509:00:00Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac...
03/20/201506:03:41Report of Foreign Issuer (6-k)
03/19/201510:55:30Report of Foreign Issuer (6-k)
03/19/201507:18:26March Madness: Final 4 Investing Bracket 2015
03/18/201520:39:01Amarin Argues In Court For Vascepa Exclusivity

Glaxosmithkline and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad